{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:15:59Z","timestamp":1792440959945,"version":"4.5.0"},"reference-count":124,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This meta-analysis evaluated the real-world effectiveness of onabotulinumtoxinA (BOTOX\u00ae), the first preventive treatment FDA-approved specifically for chronic migraine in 2010.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically reviewed onabotulinumtoxinA observational data in chronic migraine published between 1 January 2010 and 31 March 2021. Random-effects models evaluated available data for primary and secondary endpoints defined in onabotulinumtoxinA pivotal trials at approximately 24 weeks and 52 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 44 full-text eligible studies (29 prospective; 13 retrospective; 2 other), seven evaluated change from baseline (mean[confidence interval]) at \u223c24 weeks and \u223c52 weeks, respectively, for onabotulinumtoxinA in: number of headache days\/month: (\u201310.64 [\u201312.31, \u20138.97]; \u201310.32 [\u221214.92, \u20135.73]); number of days of acute headache pain medication intake per month (\u20137.40 [\u201313.04, \u20131.77]; overlapping CIs at 52 weeks); total Headache Impact Test-6 score (\u201311.70 [\u201313.86, \u20139.54]); \u201311.80 [14.70, \u20138.90]); and Migraine-Specific Quality-of-Life v2.1 score (MSQ; 23.60 [CI: 21.56, 25.64]; 30.90 [CI: 28.29, 33.51]). At \u223c24 weeks onabotulinumtoxinA showed total Migraine Disability Assessment score of 44.74 [28.50, 60.99] and \u226550% reduction in migraine days response rate of 46.57% [29.50%, 63.65%]. A sensitivity analysis at study-end suggested durability of onabotulinumtoxinA effectiveness on MSQ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The meta-analysis reflecting real-world practice broadly corroborated with evidence from pivotal and long-term open-label studies of onabotulinumtoxinA in chronic migraine preventive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024221123058","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T01:02:42Z","timestamp":1662685362000},"page":"1543-1564","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":52,"title":["Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data"],"prefix":"10.1177","volume":"42","author":[{"given":"Michel","family":"Lanteri-Minet","sequence":"first","affiliation":[{"name":"Pain Department and FHU InovPain, C\u00f4te Azur University, Centre Hospitalier Universitaire de Nice, Nice, France"},{"name":"INSERM U1107 Migraine and Trigeminal Pain, Auvergne University, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-5013","authenticated-orcid":false,"given":"Anne","family":"Ducros","sequence":"additional","affiliation":[{"name":"Neurology Department, Gui de Chauliac Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Francois","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Olewinska","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Nikodem","sequence":"additional","affiliation":[{"name":"Creativ-Ceutical, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Dupont-Benjamin","sequence":"additional","affiliation":[{"name":"Allergan (an AbbVie company), Tour CBX, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"bibr1-03331024221123058","unstructured":"National Institute of Neurological Disorders. Migraine information page. https:\/\/www.ninds.nih.gov\/Disorders\/All-Disorders\/Migraine-Information-Page (2012, accessed 11 May 2021)."},{"key":"bibr2-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr3-03331024221123058","unstructured":"The Migraine Trust. Chronic migraine, https:\/\/www.migrainetrust.org\/about-migraine\/types-of-migraine\/chronic-migraine\/ (2021, accessed 11 May 2021)."},{"key":"bibr4-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0"},{"key":"bibr5-03331024221123058","unstructured":"International Headache Society.\n                      Part I. The primary headaches\n                      . https:\/\/ichd-3.org\/1-migraine\/1-3-chronic-migraine\/. (2019, accessed 12 September 2020)."},{"key":"bibr6-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364676"},{"key":"bibr7-03331024221123058","first-page":"41","volume":"59","author":"Burch R","year":"2019","journal-title":"Headache"},{"key":"bibr8-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2212"},{"key":"bibr9-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1038-4"},{"key":"bibr10-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02632-0"},{"key":"bibr11-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13275"},{"key":"bibr12-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.10.005"},{"key":"bibr13-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0894-6"},{"key":"bibr14-03331024221123058","unstructured":"National Institute for Health and Care Excellence. Headaches in over 12s: diagnosis and management. CG150. https:\/\/www.nice.org.uk\/guidance\/cg150\/chapter\/Recommendations#management-2. (2021, accessed 16 May 2021)."},{"key":"bibr15-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-009-0179-2"},{"key":"bibr16-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"bibr17-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"bibr18-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"bibr19-03331024221123058","unstructured":"AJMC. Emerging therapies and preventive treatments for migraine, https:\/\/ajmc.s3.amazonaws.com\/_media\/_pdf\/AJMC_A787_Migrane_Whitepaper_posting.pdf (2017, accessed 5 February 2019)."},{"key":"bibr20-03331024221123058","unstructured":"Ashina S. Identifying barriers to care-seeking, diagnosis, and preventive medication among those with migraine: Results of the OVERCOME study.\n                      Presented at the 62nd Annual Scientific Meeting of the American Headache Society.\n                      2020; San Diego, California, USA."},{"key":"bibr21-03331024221123058","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.18058"},{"key":"bibr22-03331024221123058","first-page":"47","volume":"28","author":"Yelland E","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"bibr23-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"bibr24-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13202"},{"key":"bibr25-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13829"},{"key":"bibr26-03331024221123058","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10194-019-1020-1","volume":"20","author":"Pozo-Rosich P","year":"2019","journal-title":"J Headache Pain"},{"key":"bibr27-03331024221123058","unstructured":"US Food and Drug Administration. QULIPTA (atogepant), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf. (2021, accessed 1 December 2021)."},{"key":"bibr28-03331024221123058","unstructured":"European Medicines Agency. Atogepant, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002530-pip01-18. (2020, 1 December 2021 December)."},{"key":"bibr29-03331024221123058","unstructured":"US Food and Drug Administration. NURTEC (rimegepant), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212728s006lbl.pdf. (2020, accessed 1 December 2021)."},{"key":"bibr30-03331024221123058","unstructured":"European Medicines Agency. Rimegepant, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002812-pip02-20. (2021, accessed 1 December 2021)."},{"key":"bibr31-03331024221123058","unstructured":"US Food and Drug Administration. VYEPTI (eptinezumab-jjmr) injection, for intravenous use. Initial US Approval. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761119s000lbl.pdf (accessed 7 December 2021)."},{"key":"bibr32-03331024221123058","unstructured":"European Medicines Agency. Eptinezumab, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002243-pip01-17-m01. (2021, accessed 1 December 2021)."},{"key":"bibr33-03331024221123058","unstructured":"US Food and Drug Administration. AIMOVIG (erenumab-aooe) injection, for subcutaneous use, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf. (2018, accessed 16 May 2021)."},{"key":"bibr34-03331024221123058","unstructured":"European Medicines Agency. Erenumab, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig. (2021, accessed 1 December 2021)."},{"key":"bibr35-03331024221123058","unstructured":"European Medicines Agency. Ajovy (fremanezumab), http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy. (2019, accessed 1 December 2021)."},{"key":"bibr36-03331024221123058","unstructured":"US Food and Drug Administration. AJOVY (fremanezumab), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761089s000lbl.pdf. (2018, accessed 1 December 2021)."},{"key":"bibr37-03331024221123058","unstructured":"European Medicines Agency. Galcanezumab, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emgality. (2021, accessed 1 December 2021)."},{"key":"bibr38-03331024221123058","unstructured":"US Food and Drug Administration. EMGALTY (galcanezumab), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761063s000lbl.pdf. (2019, accessed 1 December 2021)."},{"key":"bibr39-03331024221123058","unstructured":"US Food and Drug Administration. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5302lbl.pdf. (2017, accessed 11 May 2021)."},{"key":"bibr40-03331024221123058","unstructured":"Electronic Medicines Compendium. Botox 200 Units Powder for solution for injection, https:\/\/www.medicines.org.uk\/emc\/product\/436\/smpc (2020, accessed 16 May 2021)."},{"key":"bibr41-03331024221123058","unstructured":"MHRA. M.H.p.R.A. BOTOX 50 Allergan Units Powder for solution for injection (Botulinum Toxin Type A), https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/61c8e659aa05dd44228dd89360c8d8b77288ed18. (2021, accessed 1 December 2021)."},{"key":"bibr42-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13653"},{"key":"bibr43-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"bibr44-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15199"},{"key":"bibr45-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677"},{"key":"bibr46-03331024221123058","unstructured":"The Innovative Medicines Initiative (IMI). RWE Navigator, 2020. https:\/\/rwe-navigator.eu\/policies-and-perspectives\/. (accessed 6 June 2021)."},{"key":"bibr47-03331024221123058","unstructured":"London School of Economics and Political Science. Policy challenges around real world evidence adoption in Europe, https:\/\/www.lse.ac.uk\/business-and-consultancy\/consulting\/assets\/documents\/rwe-in-europe-paper-v.pdf. (2018, accessed 6 June 2021)."},{"key":"bibr48-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4297"},{"key":"bibr49-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415613612"},{"key":"bibr50-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13089"},{"key":"bibr51-03331024221123058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"The American Headache Society","year":"2019","journal-title":"Headache"},{"key":"bibr52-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1524751"},{"key":"bibr53-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1207\/S15328031US0202_02"},{"key":"bibr54-03331024221123058","first-page":"196","volume":"13","author":"Tufanaru C","year":"2015","journal-title":"JBI Evidence Imp"},{"key":"bibr55-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300129"},{"key":"bibr56-03331024221123058","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Green JHS.","year":"2008"},{"key":"bibr57-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"bibr58-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"bibr59-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"bibr60-03331024221123058","unstructured":"The Migraine Trust. Research. https:\/\/migrainetrust.org\/what-we-do\/our-commitment-to-research\/ (2021, accessed 30 November 2021)."},{"key":"bibr61-03331024221123058","unstructured":"American Headache Society. https:\/\/americanheadachesociety.org\/. (accessed 30 November 2021)."},{"key":"bibr62-03331024221123058","unstructured":"European Headache Federation. https:\/\/www.ehf-headache.com\/federation\/publications\/office-journal. (2021, accessed 30 November 2021)."},{"key":"bibr63-03331024221123058","unstructured":"American Academy of Neurology. https:\/\/www.aan.com\/. (2021, accessed 30 November 2021)."},{"key":"bibr64-03331024221123058","unstructured":"International Society for Pharmacoeconomics and Outcomes Research. https:\/\/www.ispor.org\/. (2021, accessed 30 November 2021)."},{"key":"bibr65-03331024221123058","unstructured":"EU Clinical Trials Register.\n                      Clinical trials\n                      . https:\/\/www.clinicaltrialsregister.eu\/. (2021, accessed 30 November 2021)."},{"key":"bibr66-03331024221123058","unstructured":"Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses, http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (2015, accessed 6 July 2022)."},{"key":"bibr67-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"bibr68-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0784-4"},{"key":"bibr69-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"bibr70-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"bibr71-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_1.S20"},{"key":"bibr72-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989247"},{"key":"bibr73-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"bibr74-03331024221123058","volume-title":"Users\u2019 Guide to the Medical Literature. A Manual for Evidence-Based Clinical Practice","author":"Murad MH","year":"2015","edition":"3"},{"key":"bibr75-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"bibr76-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0723-4"},{"key":"bibr77-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13617"},{"key":"bibr78-03331024221123058","first-page":"S60","volume":"25","author":"Taddei-Allen P","year":"2019","journal-title":"J Managed Care Spec Pharm"},{"key":"bibr79-03331024221123058","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11090504"},{"key":"bibr80-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/head.13693"},{"key":"bibr81-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2020.07.075"},{"key":"bibr82-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-0978-9"},{"key":"bibr83-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1386-8"},{"key":"bibr84-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-019-00862-5"},{"key":"bibr85-03331024221123058","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00655"},{"key":"bibr86-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0976-1"},{"key":"bibr87-03331024221123058","first-page":"94","volume":"58","author":"Boudreau G.","year":"2018","journal-title":"Headache"},{"key":"bibr88-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13523"},{"key":"bibr89-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2662-2"},{"key":"bibr90-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0591-3"},{"key":"bibr91-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-016-2568-z"},{"key":"bibr92-03331024221123058","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nrl.2016.09.004","volume":"33","author":"Sanz AC.","year":"2018","journal-title":"Neurologia"},{"key":"bibr93-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1030-z"},{"key":"bibr94-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01157-8"},{"key":"bibr95-03331024221123058","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00678"},{"key":"bibr96-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01113-6"},{"key":"bibr97-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0781-7"},{"key":"bibr98-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04283-y"},{"key":"bibr99-03331024221123058","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00808"},{"key":"bibr100-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68149-1"},{"key":"bibr101-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.01.054"},{"key":"bibr102-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2013.09.006"},{"key":"bibr103-03331024221123058","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10194-018-0868-9","volume":"19","author":"Alessiani M.","year":"2018","journal-title":"J Headache Pain"},{"key":"bibr104-03331024221123058","first-page":"S248","volume":"40","author":"Corbelli I.","year":"2019","journal-title":"Neurol Sci"},{"key":"bibr105-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01147-6"},{"key":"bibr106-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.03.001"},{"key":"bibr107-03331024221123058","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v5.i4.80"},{"key":"bibr108-03331024221123058","unstructured":"Argueta-Figueroa L. ROBINS-I or Newcastle Ottawa Scale (NOS) or AXIS: which has better validity and should there be a preference for either based on our field of work? https:\/\/www.researchgate.net\/post\/ROBINS-I_or_Newcastle_Ottawa_Scale_NOS_or_AXIS_which_has_better_validity_and_should_there_be_a_preference_for_either_based_on_our_field_of_work\/5ef23a4e177d9528634b6ce4\/citation\/download. (2020, accessed 5 July 2022)."},{"key":"bibr109-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14028"},{"key":"bibr110-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13657"},{"key":"bibr111-03331024221123058","first-page":"P98","volume":"18","author":"Belv\u00eds R.","year":"2018","journal-title":"J Headache Pain"},{"key":"bibr112-03331024221123058","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/WNL.94.15_supplement.714","volume":"94","author":"Boudreau G","year":"2020","journal-title":"Neurology"},{"key":"bibr113-03331024221123058","first-page":"154","volume":"27","author":"Boudreau G","year":"2020","journal-title":"Eur J Neurol"},{"key":"bibr114-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1159\/000499764"},{"key":"bibr115-03331024221123058","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0920-9","volume":"19","author":"Garcia-Azorin D.","year":"2018","journal-title":"J Headache Pain"},{"key":"bibr116-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-015-2140-2"},{"key":"bibr117-03331024221123058","first-page":"21","volume":"36","author":"Grazzi L.","year":"2016","journal-title":"Cephalalgia"},{"key":"bibr118-03331024221123058","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00586"},{"key":"bibr119-03331024221123058","first-page":"333","volume":"37","author":"Kennedy G.","year":"2017","journal-title":"Cephalalgia"},{"key":"bibr120-03331024221123058","first-page":"547","volume":"24","author":"Navarrete Perez JJ.","year":"2017","journal-title":"Eur J Neurol"},{"key":"bibr121-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0957-z"},{"key":"bibr122-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny282"},{"key":"bibr123-03331024221123058","volume":"18","author":"Romoli M","year":"2017","journal-title":"J Headache Pain"},{"key":"bibr124-03331024221123058","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-018-0511-5"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221123058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024221123058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221123058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:40Z","timestamp":1777387780000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/03331024221123058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":124,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/03331024221123058"],"URL":"https:\/\/doi.org\/10.1177\/03331024221123058","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]}}}